Key clinical point: The BALL score identified a subset of patients (around 50%) who particularly benefit from single-agent ibrutinib.
Major finding: The patients likely to benefit from ibrutinib had a survival rate of 85% at 3 years.
Study details: A two-institution study of 111 patients with CLL treated with ibrutinib.
Disclosures: The authors reported that they had no conflicts.
Molica S et al. Leuk Res. 2020 Jun 10. doi: 10.1016/j.leukres.2020.